close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by T-knife Therapeutics

T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Appoints Christoph Broja to its Board of Directors
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics to Participate in Two Investor Conferences in March
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
From T-knife Therapeutics
Via GlobeNewswire
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
From T-knife Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today